Avience Biomedicals SME: Check IPO Date, Live Subscription and Key Details
Avience Biomedicals Limited, incorporated in June 2024, is an ISO-certified healthcare and biotechnology solutions company. The enterprise specializes in manufacturing, supplying, and exporting high-precision molecular diagnostic formulations, in-vitro diagnostics (IVD) rapid test kits, serology products, and automated biochemistry and hematology analyzers. Operating entirely on business-to-business (B2B) and business-to-government (B2G) frameworks, Avience provides cost-effective diagnostics to premier hospital networks, pathology labs, and research institutions. Its manufacturing footprint is centered in Noida, Uttar Pradesh, with its technical pipelines expanding to cover emergency critical care lines, including oxygen concentrators and viral transport solutions.
Price Range
₹196.0 - ₹208.0
Issue Size
₹30.24 Cr
Lot Size
600 shares
IPO Type
NSE SME
GMP
₹70(+33.65%)
Est. Listing Price
₹278
Estimate Profit
₹84,000
Retail Portion
35.08%
Key Metrics
Check Live GMPGMPFace Value
₹10
EPS
12.56
P/E Ratio
16.56
RoNW
22.38%
ROE
22.38%
Debt to Equity
0.94
Advertisement
Timeline
IPO Opens
18 Jun
IPO Closes
22 Jun
Allotment
23 Jun
Listing
25 Jun
IPO Timeline & Listing Details
| Event | Date | Details |
|---|---|---|
| IPO Open Date | 18 June 2026 | Subscription starts |
| IPO Close Date | 22 June 2026 | Subscription ends |
| Allotment Date | 23 June 2026 | Allotment |
| Listing Date | 25 June 2026 | Listing |
Investment Categories
| Category | Lots | Amount |
|---|---|---|
Individual | 2 | ₹2,49,600 |
SHNI (Min) | 3 | ₹3,74,400 |
SHNI (Max) | 8 | ₹9,98,400 |
BHNIAbove ₹10,00,000 | 9 | ₹11,23,200 |
IPO Reservation Details
| Category | Reservation |
|---|---|
| QIB (Qualified Institutional Buyer) | 49.83% |
| NII (Non-Institutional Investor) | 15.09% |
| SHNI (Small Non-Institutional Investor) | 4.75% |
| BHNI (Big Non-Institutional Investor) | 9.49% |
| Retail | 35.08% |
| Market Maker | 5.65% |
| Total | 100.00% |
IPO Objectives
- Part financing capital expenditure requirements towards setting up a new diagnostic and medical equipment manufacturing unit at the dedicated Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA) in Gautam Buddha Nagar, Uttar Pradesh (₹15.96 Cr).
- Funding ongoing incremental working capital requirements of the company (₹8.25 Cr).
- General Corporate Purposes.
Strengths
- The company builds a Clean Product Diversity Moat, offering a comprehensive diagnostic matrix that scales seamlessly across quick-turnaround rapid test kits, advanced biochemistry analyzers, and molecular PCR assays.
- It benefits from Strategic Medical Park Integration, as capital allocations are directed entirely into a new greenfield facility located inside the specialized YEIDA Medical Device Park zone, yielding significant macro logistics and supply chain advantages.
- The business commands Strong Specialized Sector Margins, recording solid operational parameters with an active PAT margin of 15.86% and an EBITDA margin of 24.70% as of late 2025.
- It maintains strong B2G Tender Runway Visibility, with a specialized focus on institutional B2B laboratories and structural, high-volume government medical procurement contracts.
- The issue enjoys Positive Market Sentiments, capturing healthy early grey market momentum with an active premium quote tracking at ₹70, suggesting a projected entry layer near ₹278 per share.
Weaknesses
- The firm has an Incredibly Brief Corporate Track Record, having been incorporated exceptionally recently in June 2024, which presents a very short baseline historical performance arc for long-term operational validation.
- It faces High Concentration & Regulatory Risks, as its core revenues and operational clearances remain heavily bound to stringent drug compliance certifications, institutional purchase milestones, and government procurement timelines.
- The business manages Substantial Balance Sheet Leverage, with total borrowings growing to ₹26.73 Cr by early 2026, leading to an elevated pre-issue debt-to-equity matrix layer tracking at 0.94.
Advertisement
Financial Performance
| Period Ended | 31 Jan 2026 (10M) | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Assets (₹ Cr.) | 66.07 | 56.52 | 34.65 |
| Revenue (₹ Cr.) | 41.94 | 45.97 | 24.37 |
| PAT (₹ Cr.) | 5.74 | 7.23 | 2.14 |
| Net Worth (₹ Cr.) | 28.52 | 22.78 | 6.21 |
Peer Comparison
| Company | P/B Ratio | P/E Ratio | RONW (%) | Net Worth (₹ Cr.) |
|---|
Subscription Details
No daily bids available.
No subscription statistics available.
Advertisement
Company Details
- Avience Biomedicals Ltd.
- C-11, Block-C, Community Centre, Janakpuri A-3, Delhi, New Delhi, 110058
- 1800-12-04-636
- info@avienbio.com
- https://avienbio.com/
Registrar Details
- Skyline Financial Services Pvt.Ltd.
- 02228511022
- ipo@skylineonline.com
- https://www.skylinerta.com/
Frequently Asked Questions
What does Avience Biomedicals do?
Avience Biomedicals manufactures and supplies medical diagnostic products, including in-vitro diagnostic (IVD) test kits, biochemistry analyzers, and molecular diagnostic solutions for healthcare institutions and laboratories.
What are the IPO dates for Avience Biomedicals SME IPO?
The Avience Biomedicals SME IPO will open for subscription on June 18, 2026, and close on June 22, 2026.
What is the price band and minimum investment for Avience Biomedicals IPO?
The IPO price band is fixed at ₹196 to ₹208 per share. Retail investors need to apply for a minimum of 2 lots (1,200 shares), requiring an investment of ₹2,49,600 at the upper price band.
What is the Grey Market Premium (GMP) of Avience Biomedicals IPO today?
As of June 15, 2026, the Grey Market Premium (GMP) of Avience Biomedicals IPO is around ₹70 per share, indicating an estimated listing price of about ₹278.
Where will Avience Biomedicals IPO be listed?
Avience Biomedicals IPO is proposed to be listed on NSE SME (NSE Emerge), with the tentative listing date set for June 25, 2026.
Loading comments...